v3.10.0.1
Other (Income)/Deductions - Net - Footnotes - Royalty Income (Details) - USD ($)
$ in Millions
 1 Months Ended 12 Months Ended
Oct. 31, 2016
Oct. 31, 2016
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Royalty income [1]     $ 495 $ 499 $ 905
Xtandi [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Royalty income       176  
Collaborative Arrangement, Co-promotion [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Royalty revenue, term 36 months        
Collaborative Arrangement, Co-promotion [Member] | Enbrel [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Decrease in royalty revenue       $ 470  
Royalty revenue, term   36 months      
[1] Royalty-related income decreased in 2017, primarily due to lower royalty income for Enbrel of $470 million in 2017, compared to 2016, resulting from the expiration on October 31, 2016 of the 36-month royalty period under the collaboration agreement for Enbrel in the U.S. and Canada (the collaboration period under the agreement expired on October 31, 2013), partially offset by increases in Xtandi royalty-related income of $176 million in 2017, compared to 2016.